New study explores Evolocumab's impact on inflammation in diabetic heart patients
Knowledge-focused
Completed
This study looked at how evolocumab (Repatha) affects markers of inflammation and blood vessel health in people with type 2 diabetes and heart disease. 41 participants received either evolocumab or a placebo every 4 weeks for 3 doses. The goal was to understand how this drug migh…
Phase: PHASE4 • Sponsor: Robert Rosenson • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:08 UTC